LLY
LLY clinical trials: ELI LILLY & Co
Every trial on ClinicalTrials.gov where ELI LILLY & Co is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 2,918
- Trials linked
- 2,139
- As lead sponsor
- 779
- As collaborator
- 8
- Primary completions as lead sponsor, next 90 days
LLY on the catalyst calendar · LLY registry changes
- Primary completion Oct 8, 2026ActualPhase 1NCT07794592A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy ParticipantsEli Lilly and Company · Healthy VolunteersCompletedLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimatePhase 3NCT07881458A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesEli Lilly and Company · ObesityRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1NCT07339722A Study of LY4515100 in Healthy ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 1NCT07915245A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise HealthyEli Lilly and Company · ObesityRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1NCT07914738A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Eli Lilly and Company · Lipoprotein(a)RecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2029Sponsor estimatePhase 3NCT07900633A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskEli Lilly and Company · ObesityNot yet recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1NCT07881887A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesEli Lilly and Company · ObesityRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimatePhase 3NCT07881432A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesEli Lilly and Company · ObesityNot yet recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT07867340A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants...Eli Lilly and Company · C-Reactive ProteinRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07867327A Study of LY4515100 in Healthy Male ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 1NCT07843459A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Eli Lilly and Company · Healthy VolunteersRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1NCT07787182A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's DiseaseEli Lilly and Company · Healthy VolunteersRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07738614A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2026ActualPhase 1NCT07701083A Study of Eloralintide (LY3841136) in Healthy ParticipantsEli Lilly and Company · Healthy VolunteersCompletedLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2026ActualPhase 1NCT07426380A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionEli Lilly and Company · Kidney DiseaseCompletedLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT07090785A Study of LY4088044 in Healthy ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1NCT06945406A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesEli Lilly and Company · Diabetes Mellitus, Type 1RecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2026ActualPhase 2NCT06643728A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults...Eli Lilly and Company · ObesityCompletedLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2026ActualPhase 3NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With...Eli Lilly and Company · Type 2 DiabetesActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT07945314A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsEli Lilly and Company · Healthy ParticipantsNot yet recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT07943091A Study of LY3945262 in Healthy ParticipantsEli Lilly and Company · Healthy VolunteersNot yet recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 1NCT07883590A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).Eli Lilly and Company · Amyotrophic Lateral SclerosisNot yet recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2026ActualPhase 1NCT07707375A Study of LY4268989 (MORF 057) in Healthy ParticipantsEli Lilly and Company · HealthyCompletedLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 3NCT05556512A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2030Sponsor estimatePhase 1NCT07046923A Study of LY4175408 in Participants With Advanced CancerEli Lilly and Company · Carcinoma, Non-Small-Cell LungActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2,893 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner